Pharmaceutical Preparations
Arbutus Biopharma Corp (ABUS) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 76/100 — a percentile rank of Arbutus Biopharma Corp’s fundamentals against Manufacturing peers.
Is Arbutus Biopharma Corp overvalued? P/S looks undervalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Consensus: Buy from 10 analysts (Buy 8 · Hold 2).
Average price target: $8.50 (+111.1% vs $4.03); range $8–$8.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 0 · Open-market sells: 13 · Net: −$2.0M
Cluster · 14 insiders buying.
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!